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ABSTRACT
Objectives: Class D oxacillinases are frequently acquired by gram negative bacteria in general and P. aeruginosa in par-
ticular. P. aeruginosa is commonly implicated in causing nosocomial infections. The evolution of antibiotic resistance in 
P. aeruginosa and the acquisition of blaOXA genes interfere with successful treatment.
Methods: A total of 49 clinical isolates of P. aeruginosa were obtained from Rafidia Hospital, West Bank, Palestine. 
Antimicrobial susceptibility testing of the isolates was performed by the standard disc diffusion method following the 
guidelines of CLSI. The prevalence of class D β-lactamases (OXA groups I, II and III) as well as the pseudomonas specific 
enzymes (CARB-3) were determined by PCR.
Results: Susceptibility of P. aeruginosa to carbapenems was the highest 89%, and lowest to ticarcillin/clavulanic acid 
70%. This study revealed that P. aeruginosa produced oxacillinase enzymes at rates of: OXA-10 (40.8%), OXA-2 (20.4%) 
and OXA-1 (18.4%). All ceftazidime resistant strains expressed OXA-1 and OXA-2, 18.4%. PSE group was expressed in 
10.2%.
Conclusions: This is the first research conducted to investigate the correlation between OXA genes (blaOXA-1, bla-
OXA-2 and blaOXA-10) and antimicrobial resistance among P. aeruginosa clinical isolates in Palestine. The results ob-
tained could contribute to better treatment and reduction of the evolution of resistant strains. In addition, it will provide 
important information regarding the geographical distribution of class D β-lactamases. J Microbiol Infect Dis 2013; 3(2): 
56-60
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Filistin, Batı Şeria’da izole edilen Pseudomonas aeruginosa izolatlarında β-laktamaz varlığı 
ve antibiyotik duyarlılıkları 
ÖZET
Amaç: D sınıfı oksasilinazlar gram negatif basiller içinde ve de özellikle P. aeruginosa kökenlerinde yaygındır. P. aeru-
ginosa hastane enfeksiyonlarının sık nedenlerinden biridir. P. aeruginosa kökenlerinde antibiyotik direncinin ve blaOXA 
genlerinin kazanılması tedavi başarısını etkiler. Bu çalışmada P. aeruginosa kökenlerinde antibiyotik direnci ve blaOXA 
gen varlığının tedavi başarısı üzerine etkileri araştırıldı.
Yöntemler: Toplam 49 klinik P. aeruginosa izolatı Filistin’de bulunan Rafidia Hastanesinden elde edildi. Antimikrobiyal 
duyarlılık testleri standart disk difüzyon metodu ile CLSI standartlarına göre yapıldı. D grubu β-lactamaz (OXA grop I, II 
ve III) sıklığı ve pseudomonasa özgün enzimlerin (CARB-3) varlığı PCR yöntemiyle araştırıldı.
Bulgular: P. aeruginosa kökenlerinde en yüksek duyarlılık karbapenemlere (%89) ve en düşük duyarlılık ise tikarsilin/
klavulanik aside (%70) karşı saptandı. Bu çalışmanın sonuçlarına göre; P. aeruginosa kökenlerinde OXA-10 oranı %40,8, 
OXA-2 %20,4 ve OXA-1 %18,4. Seftazidime dirençli kökenlerin hepsi OXA-1 taşırken %18,4’ü OXA-11 taşıyorlardı. PSE 
grubu salgılanması ise %10,2 idi.
Sonuç: Bu çalışma Filistin’deki P. aeruginosa izolatları üzerinde yapılan ve OXA genleriyle (blaOXA-1, blaOXA-2 ve bla-
OXA-10 ) antimikrobiyal direnç arasındaki ilişkiyi araştıran ilk çalışmadır. Sonuçlarımız dirençli kökenlerdeki tedavi pren-
siplerini anlamaya yardımcı oldu ve D grubu β-laktamazların coğrafi dağılımı hakkında bilgi sahibi olmamızı sağladı.
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic 
pathogen commonly involved in infections of the 
immunosuppressed patients and a major cause of 
nosocomial infections.1-4 P. aeruginosa is intrinsical-
ly resistant to various classes of antibiotics through 
constitutive  expression  of  various  efflux  pumps, 
production of β-lactamases and decreased permea-
bility of the outer membrane.5-7 Acquired resistance 
by P. aeruginosa is mediated by the acquisition of 
resistance genes for β-lactamases, mutations and 
fluoroquinolones,  over  expression  of  the  efflux 
pumps and decreased expression of porin proteins. 
Resistance of P. aeruginosa to aminoglycosides 
involves their inactivation by several modifying en-
zymes which inhibit the binding of these antibiotics 
to their target.2,6-8 P. aeruginosa is capable of de-
veloping multidrug resistance causing treatment 
failure and resulting in increased rates of morbidity 
and mortality.9,10
Although  extended  spectrum  β-lactamases 
(ESBLs) of classes A, B and D have recently been 
reported in P. aeruginosa, OXA and PSE types are 
the most prevalent β-lactamases encountered.11,12 
Genes encoding oxacillinase enzymes are intrinsic 
in gram negative bacteria including P. aeruginosa.13 
The acquired OXA genes can have a narrow or ex-
panded spectrum of hydrolysis of antibiotics.14 The 
prevalence of OXA type β-lactamases in P. aerugi-
nosa had never been investigated in Palestine. The 
aim of this study was to assess the antimicrobial 
susceptibility of clinical isolates of P. aeruginosa, 
the  rate  of Ambler  group A  and Ambler  group  D 
β-lactamases in our isolates.
METHODS
Bacterial isolates
A total of 49 isolates of P. aeruginosa were obtained 
in  2010  from  various  clinical  sources  including 
wounds (21), sputum (8), urine (6), sores (4), Ear 
(4), blood (3), CSF (1) and other sites (2). There 
were 20 isolates from the burn unit, 13 isolates from 
the intensive care unit, 7 from surgical ward and 
9 from outpatient clinics. The ages of the patients 
ranged from newborn babies to 77 years with 28 fe-
males and 21 males. To avoid duplication, one sam-
ple for each patient was obtained. The isolates were 
obtained from Rafidia Surgical Hospital in Nablus, 
West Bank, Palestine.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing of P. aeruginosa 
isolates was determined by disc diffusion following 
the recommendations and guidelines of the Clinical 
Laboratory Standard Institute (CLSI).15,16 The anti-
biotics tested were: Imipenem (10 ug), meropenem 
(10 ug), gentamicin (10 ug), ceftazidime (30 ug), 
ciprofloxacin (5 ug), ticarcillin (75 ug) and ticarcillin/
clavulanic acid (75 ug/10 ug), (all from Oxoid, Bak-
ingstoke,  United  Kingdom).  P. aeruginosa  ATCC 
27853 was used as a quality control to ensure the 
accuracy of the antimicrobial susceptibility results. 
The zone of inhibition was precisely measured us-
ing  Vernier  Caliper  and  interpreted  according  to 
CLSI.16 Extended spectrum oxacillinases in P. ae-
ruginosa was detected by the double disk synergy 
test according to Didier et al.17 using ceftazidime re-
sistant isolates with imipenem. 
DNA extraction
Bacterial  DNA  was  extracted  by  emulsifying  two 
to three colonies taken from an overnight culture 
in 200 ul PBS and heated at 95°C for 10 minute. 
The suspension was then centrifuged at 12,000 rpm 
for two minutes and the supernatant containing the 
DNA was stored at -20°C to be used for amplifica-
tion by PCR.
PCR
The primers used for the amplifications were ob-
tained from Invitrogen and specified in Table 1. The 
sequences and the size of each amplicon have 
been specified previously by Bert et al.18 Amplifica-
tion was conducted in a total volume of 25 µL using 
C-1000 thermal cycler (BioRad, USA). PCR condi-
tions were as follows: 3 minutes at 95°C, followed 
by 40 cycles of 20 seconds at 95°C, 30 seconds at 
primer specific annealing temperature (Table 1), 30 
second at 72°C and a final extension at 72°C for 
5 minutes. The PCR products were run on a 1.5% 
agarose gel in 1x TAE buffer containing 2.0 µg/ml 
ethidium bromide. Samples were electrophoresed 
at 92 V/cm for 30 minutes. The size of the DNA am-
plicons was determined by comparing it with a 100 
bp DNA ladder (Gene Dire) included with each gel. 
Samples were visualized under UV and then photo-
graphed using the Gel Doc system (BioRad, USA).Essawi T, et al. Ceftazidime resistance and OXA-type Oxacillinases in P. aeruginosa 58
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Table 1. Primer sets used and amplicon sizes to determine the presence of bla OXA genes and PSE group in the clini-
cal isolates of P. aeruginosa
Primer pair Target 5’ - 3’ sequence Product size (bp) Annealing (°C)
OXA10-F
OXA10-R
OXA group I 5-TCAACAAATCGCCAGAGAAG-3
5 - CCACTCAACCCATCCTACCC -3
276 56
OXA2- F
OXA2- R
OXA Group II 5- AAGAAACGCTACTCGCCTGC -3
5 - CCACTCAACCCATCCTACCC -3
478 58
OXA1-F
OXA1-R
OXA Group III 5-TTTTCTGTTGTTTGGGTTTT-3
5-TTTCTTGGCTTTTATGCTTG-3
427 51.5
CARB3-F
CARB3-R
PSE 5-ACCGTATTGAGCCTGATTTA-3
5-ATTGAAGCCTGTGTTTGAGC-3
321 52.7
The strains that were positive for the different 
β-lactamase genes tested were subsequently used 
as positive controls. Primers were selected to deter-
mine the carriage of genes for OXA-groups I (bla-
OXA-10), II (blaOXA-2) and III (blaOXA-1) and the 
PSE group (PSE-1, PSE-4, CARB-3). A represen-
tative photograph of the gel for the PCR results is 
shown in Figure 1.
Figure 1. Agarose gel electrophoresis for the amplifica-
tion of blaOXA genes and CARB3 genes. Lane 1, 100 bp 
DNA ladder; Lane 2, blaOXA-1; Lane 3, blaOXA-2; Lane 
4, CARB3; Lane 5, blaOXA-10; Lane 6, negative control, 
Lane 7, blank.
The  percentage  of  OXA  groups  I,  II  and  III 
among  the  isolates  tested  was  40.8%  (20/49), 
20.4% (10/49) and 22.5% (11/49). The percentage 
of OXA group I and OXA group II carried by the 
same isolate was 18.4% (9/49). PSE group was car-
ried by 10.2% of the isolates (5/49). All ceftazidime 
resistant isolates, 16.3% (8/49) carried the gene for 
OXA group I.
RESULTS
Antimicrobial susceptibility testing
The results of the antimicrobial susceptibility test-
ing for P. aeruginosa are shown in Table 2. The car-
bapenems (imepenem and meropenem) showed 
the highest activity of 89.8% against this organism 
followed by ciprofloxacin, gentamicin, ceftazidime, 
ticarcillin and ticarcillin/clavulanic acid. Multidrug re-
sistance is defined as the ability to resist three dif-
ferent classes of antibiotics or more. In the present 
study 22.4% (11/49) were multidrug resistant. Six 
of the multidrug resistant isolates were resistant to 
all antibiotics tested except two of them were sus-
ceptible only to ciprofloxacin. The rate of extended 
spectrum oxacillinases in P. aeruginosa was 8.2% 
(4/59).
Table 2. Antimicrobial susceptibility results for P. aeru-
ginosa; Susceptible (S), Intermediate (I), Resistant (R), 
percentage (%).
Antibiotic S (%) I (%) R (%)
Ceftazidime 39 (79.6) 2 (4.1) 8 (16.3)
Ciprofloxacin 41(83.7) 1 (2) 7 (14.3)
Gentamicin 39 (79.6) 2 (4.1) 8 (16.3)
Imipenem 44(89.8) 0 5 (10.2)
Meropenem 44 (89.8) 0 5 (10.2)
Ticarcillin 37 (75.5) 1(2) 11 (22.5)
Timentin 35 (71.4) 0 14 (28.6)
PCR results
PCR  was  performed  to  detect  the  expression  of 
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DISCUSSION
The carriage of group D β-lactamase genes (OXA 
groups I, II and III) among clinical isolates of P. ae-
ruginosa was determined by PCR. OXA group I was 
the most commonly found among these isolates 
(40.8%). Interestingly, all ceftazidime resistant iso-
lates carried the β-lactamase gene for OXA group I.
P. aeruginosa is an opportunistic pathogen that 
causes serious infections particularly in intensive 
care units. It has been reported that significant ther-
mal injuries induce a state of immunosuppression 
that predisposes burn patients to infections.19 It has 
also been reported that septic patients in intensive 
care units suffer from compromised immune func-
tions.20 Based on this, and because the majority of 
patients in this study (33/49) were from burn unit 
and intensive care unit, it is safe to consider that 
these patients may have immunosuppressed sta-
tus, and become prone to infections.
Multidrug  resistant  strains  are  frequent  and 
pose serious problems that result in treatment fail-
ure and high mortality rates. Antibiotic susceptibility 
testing and PCR were carried out to determine the 
degree of resistance and the prevalence of Ambler 
class D enzymes among 49 clinical isolates of P. 
aeruginosa.
The antibiotic susceptibility results are shown in 
Table 2. The resistance profile of the clinical isolates 
is similar to literature published by Heintz and by 
Lister et al.7 In addition, our results are comparable 
with results obtained in neighboring Israel and Tur-
key.2 Resistance rates to ceftazidime and carbapen-
ems are similar to results obtained in Israel, while 
resistance rates to quinolones and aminoglycosides 
are higher in Israel. The resistance of P. aeruginosa 
to these antibiotics is consistently higher in Turkey.2
The prevalence of OXA type β-lactamases is 
frequently encountered in P. aeruginosa. These 
enzymes have never been investigated in Pales-
tine. The majority of β-lactamases detected in this 
study belonged to group D as compared to group 
A (63.3% versus 10.2%). In a Korean study 11, they 
reported that class D is more frequent than class A 
indicating geographical distribution of these genes. 
OXA-10 was the most common (40.8%) followed 
by OXA-1 (22.5%) and OXA-2 (20.4%). blaOXA-10 
is the most frequently encountered gene in P. ae-
ruginosa.11,21 All ceftazidime resistant isolates that 
carried  only  the  blaOXA-10  (8/49)  were  obtained 
from the intensive care unit. This indicates that the 
isolates that carry blaOXA-10 are more resistant to 
these antibiotics than the strains that do not carry it.
Four ceftazidime resistant isolates carried bla-
OXA-2 (4/9) in addition to blaOXA-10. It is interest-
ing to note that all isolates carrying the blaOXA-1 
gene (10/49) were susceptible to all antibiotics test-
ed. Most of the multidrug resistant isolates encoun-
tered in this study carried both blaOXA-10 and bla-
OXA-2 or blaOXA-10 alone. Although two of these 
isolates were resistant to all antibiotics tested, three 
isolates were only susceptible to imipenem and two 
isolates were only susceptible to ciprofloxacin.
The  acquisition  of  OXA  β-lactamases  is  fre-
quently  identified  in  gram  negative  bacteria  par-
ticularly in P. aeruginosa, Enterobacteriaceae and 
Acinetobacter species. Selective antibiotic pressure 
that develops in response to over use of β-lactam 
antibiotics particularly in hospitals can be respon-
sible for the expression and dissemination of these 
enzymes. The threat of treatment failure is amplified 
by the evolution of P. aeruginosa strains expressing 
expanded spectrum oxacillinase activity (ES-OXA).
In conclusion, the present study is the first to 
determine  the  prevalence  of  b  blaOXA-10,  bla-
OXA-2 and blaOXA-10 among clinical isolates of P. 
aeruginosa. The emergence of extended spectrum 
group  D  β-lactamases  among  P. aeruginosa iso-
lates must be taken seriously. Hospitals should take 
the necessary measures to limit the spread of this 
pathogen. This would contribute to better treatment 
and prevent their spread.
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